Invex Therapeutics Broadens Alzheimer's Research with Tessara, Conducts Direct Comparison of Exenatide Against Competing GLP-1 Agonists

Expanded Collaboration with Tessara Targets Mechanistic Differentiation in Alzheimer's Disease

On 24 April 2026, Invex Therapeutics announced the initiation of an expanded preclinical research programme with Tessara Therapeutics, a specialist in human induced pluripotent stem cell-derived disease models. This extension of their existing partnership marks a key step in Invex’s strategy to establish Exenatide as a mechanistically distinct treatment for Alzheimer's disease. The programme will employ Tessara's clinically validated ADBrain™ model, a 3D human iPSC-derived system that replicates essential pathological features of Alzheimer's disease in vitro.

Invex’s prior collaboration with Tessara yielded promising results, with Exenatide showing statistically significant improvements across several Alzheimer's disease biomarkers. Importantly, the drug exhibited potential neuroprotective effects against ferroptosis, an iron-dependent oxidative cell death pathway increasingly recognized as a major contributor to Alzheimer's neurodegeneration. This discovery offers a mechanistically differentiated approach compared to current standard-of-care therapies for Alzheimer's patients.

Head-to-Head Benchmarking and Combination Therapy Evaluation

The expanded research programme is designed around three core objectives reflecting Invex’s competitive data generation strategy. Firstly, it will conduct direct head-to-head comparisons of Exenatide against an established GLP-1 receptor agonist, allowing evaluation of efficacy and tolerability differences within the same drug class. Such comparative data could support future clinical development and strategic discussions with partners or regulators.

Secondly, the study will assess combination regimens pairing Exenatide with a current GLP-1 agonist alongside approved symptomatic Alzheimer's treatments to explore potential additive or synergistic therapeutic benefits. Thirdly, the programme will investigate novel combinations of Exenatide and GLP-1 agonists with naturally occurring factors known to synergistically improve Alzheimer's disease phenotypes. This multi-layered approach highlights Invex’s efforts to maximize the therapeutic potential of its lead compound.

Ferroptosis as a Key Mechanistic Differentiator in Neurodegeneration

Targeting ferroptosis represents a significant point of differentiation for Exenatide in the crowded Alzheimer's therapeutic landscape. Ferroptosis is an iron-dependent regulated cell death mechanism driven by oxidative stress, distinct from other well-characterized pathways. Recent studies implicate ferroptosis as a critical factor in neuronal loss in Alzheimer's disease, separate from the traditional amyloid-beta and tau targets that have dominated drug development for decades. Invex’s findings that Exenatide may protect against ferroptosis suggest it could address complementary or alternative pathological pathways in neurodegeneration.

This mechanistic insight positions Exenatide as a potentially differentiated Alzheimer's treatment option. While many current and investigational therapies focus on amyloid-beta reduction, tau modulation, or neuroinflammation, a drug active against ferroptosis could offer additional benefits, especially in combination with existing approaches. Tessara’s validated assays measuring cytotoxicity, cell viability, and ferroptosis will enable Invex to thoroughly characterize Exenatide’s cellular mechanisms compared to other agents.

Invex’s Repurposing Strategy and Product Positioning for Exenatide

Invex Therapeutics is dedicated to repurposing Exenatide, an approved drug, for neurological conditions involving raised intracranial pressure. The company markets its repurposed formulation as Presendin™. This strategy leverages Exenatide’s established safety and pharmacokinetic profile while exploring novel neurological indications. Originally developed as a glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes, Exenatide effectively lowers blood glucose and supports weight loss.

Invex’s focus on neurological indications reflects emerging evidence that GLP-1 receptor agonists possess neuroprotective and neuromodulatory properties beyond metabolic effects. Research suggests GLP-1 signalling may reduce neuroinflammation, promote neuronal survival, and modulate multiple pathological pathways implicated in neurodegenerative diseases. By targeting this area, Invex aims to tap into an underexplored therapeutic space with a drug already approved for human use, potentially streamlining regulatory pathways and reducing development costs and timelines compared to new chemical entities.

Financial Position and Operating Expense Trends

For the quarter ended 30 June 2026, Invex Therapeutics reported cash and cash equivalents of $4,016,000, down $501,000 from $4,517,000 in Q3 FY26. Operating cash outflows increased to $501,000 in Q4 FY26 from $79,000 in Q3 FY26, reflecting the expanded scope of research and development activities. The cash balance comprised $1,016,000 in bank accounts and $3,000,000 in call deposits, providing a liquidity buffer for ongoing operations.

Research and development expenses rose sharply to $379,000 in Q4 FY26 from $53,000 in Q3 FY26, primarily driven by the expanded Tessara collaboration. Administration and corporate costs totaled $135,000 in Q4 FY26, compared to $67,000 in Q2 FY26, mainly related to compliance costs as an ASX-listed company. Payments to related parties amounted to $54,000, covering director fees, consulting, and registered office expenses.

Cash Runway and Burn Rate Analysis

Invex’s cash position of $4.016 million as of 30 June 2026 is the primary funding source for ongoing R&D. The Q4 FY26 operating cash outflow of $501,000 suggests a cash runway of approximately eight quarters at the current burn rate, though actual expenditures may vary depending on research progress and collaboration investments. The company has not disclosed plans for additional financing or fundraising in this update.

Over the 12 months ending 30 June 2026, total operating cash outflows were $1,358,000, with $530,000 attributed to R&D and $945,000 to administration and corporate expenses. Interest income of $129,000 partially offset these costs. The company reported no revenue from product sales during this period, indicating it remains in a pre-commercial stage focused on research activities. Investors will likely monitor future updates for changes in cash position, burn rates, or funding announcements.

Strategic Context of GLP-1 Receptor Agonist Development

The GLP-1 receptor agonist class has attracted significant attention and investment, particularly in diabetes and obesity treatment, with multiple commercially successful compounds. Expanding GLP-1 agonist research into neurological diseases like Alzheimer's represents a new frontier. Several large pharmaceutical and biotech firms have initiated programmes exploring neuroprotective effects of GLP-1 agonists across neurodegenerative conditions. Invex’s focus on Exenatide positions it within a scientifically and commercially growing area, though it faces competition from larger, well-capitalized players.

Peer-reviewed validation of GLP-1 agonists in neurological disease models supports Invex’s development approach. Tessara’s ADBrain™ model, developed with clinical validation in mind, may help bridge preclinical data and clinical trial design. However, translating promising preclinical results into successful clinical outcomes in neurological diseases remains challenging, and positive preclinical data do not guarantee clinical or regulatory success.

Regulatory and Development Considerations for Neurological Indications

Developing treatments for neurological diseases such as Alzheimer's involves unique regulatory challenges. Agencies require biomarker assessments and cognitive outcome measures in clinical trials. Preclinical models like ADBrain™ can generate mechanistic and efficacy data to support regulatory interactions on study design and endpoints. Nonetheless, translating findings from iPSC-derived 3D models to human efficacy remains uncertain.

Repurposing Exenatide may offer regulatory advantages due to its established safety and pharmacokinetic profiles from approved indications. This could enable accelerated development if compelling efficacy data emerge for neurological uses. However, clinical evidence for safety and efficacy in the new indication will still be required. The announcement does not provide timelines for clinical trial starts, study designs, or regulatory strategies, which are expected in future disclosures.

Preclinical Risks and Commercialization Pathway

Invex remains in the preclinical stage for its Exenatide neurological programme. The expanded Tessara collaboration represents investment in further preclinical evidence to support clinical progression, though successful preclinical results do not ensure clinical success. Challenges include crossing the blood-brain barrier, avoiding off-target effects, demonstrating clinical relevance of biomarker changes, and addressing progressive disease pathology. No timeline has been disclosed for moving from preclinical to clinical trials.

As a pre-commercial company with modest cash reserves and quarterly burn, Invex’s value creation depends on successful technical and regulatory progress. The company relies on research collaborators and securing funding to continue development. While the announcement highlights technical advances and strategic focus on mechanistically novel findings, investors should recognize the substantial technical, regulatory, and financial risks on the path to an approved commercial product.